Navigation Links
BioElectronics' Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals

FREDERICK, Md., April 25, 2012 /PRNewswire/ -- BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, inexpensive drug-free topical pain and healing devices, today announced the results of a customer survey.  The results indicate that patients using BIEL's ActiPatch® therapy report a five-fold greater pain reduction than those using non-steroidal anti-inflammatory products such as ibuprofen and aspirin.

ActiPatch Therapy, which uses pulsed shortwave therapy based on large expensive machines used in clinics and hospitals, was most frequently used to treat lower back pain by participants in the survey.  Lower back pain is a major health problem in western industrialized countries and a major cause of medical expenses and disablement.

"The most widely used OTC drugs have a significant number of side effects, are minimally effective and have only short-term symptomatic relief," said Ian Rawe, Ph.D., BioElectronics Director of Clinical Research. "In comparison, ActiPatch users who participated in the survey had a five-fold greater pain reduction than persons using non-steroidal anti-inflammatory drugs, based on a comparison to published clinical data. Additionally, with ActiPatch's all-day safe pain relief, people can resume their normal daily activities."

"We are very pleased by the results of our consumer survey, which confirms our clinical studies in which ActiPatch users as compared to users of OTC pain medications, have greater pain relief and an improved quality of life," Dr. Rawe said. "An increased consumer awareness of the dangers of overuse of oral analgesics such as acetaminophen and non-steroidal anti-inflammatory drugs has significantly altered the competitive landscape for pain management therapeutics. There is significant need for an improved efficacy, competitively priced over-the-counter therapeutic agent with no side-effects."

Results of the survey, which also show that patients would recommend ActiPatch® to a friend and would themselves purchase another ActiPatch® if the need arose, can be viewed at:

About BioElectronics Corporation

BioElectronics is an award winning developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care method to reduce soft tissue pain and swelling. For more information, please visit

Contact:  E & E Communications
Paul Knopick
(949) 707-5365

SOURCE BioElectronics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioElectronics Study on Plantar Fasciitis to be Published in The Journal of Foot and Ankle Surgery
2. BioElectronics Corporation to Webcast, Live, at on October 6th
3. YesDTC Holdings and BioElectronics Receive Japanese Regulatory Review Date
4. BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date
5. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
6. BioElectronics Announces Major Clinical Trials
7. KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard
8. Survey Shows Anesthesiologists Prefer Capnography for Monitoring Adequacy of Ventilation
9. New Survey: Walgreens Customers Flock to Independent Pharmacies
10. PAREXEL Global Survey Results Identify Top Concerns of Biopharma Industry in Achieving Commercial Success
11. Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
(Date:11/26/2015)... the Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... the Netherlands has found that immunotherapy can ...
(Date:11/26/2015)... --> --> Juntendo University ... contrast weighting of MRI for patients with Multiple Sclerosis ... agreement with SyntheticMR in order to use SyMRI in clinical ... to generate multiple contrast images from a single scan and ... making it possible to both fine tune images and recreate ...
Breaking Medicine Technology:
(Date:11/27/2015)... Denver, CO (PRWEB) , ... November 27, 2015 , ... ... U.S. cities are not changing the way that they are handling security in light ... increasing police and security presence in an attempt to stop an attack from reaching ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse and ... findings on the website. Click here to read the details now. ... were treated with chemotherapy followed by EPP surgery. Among the 106 patients who relapsed, ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, I ... Hillside, N.J. "Many people catch diseases simply from sitting on such dirty toilet ... protected from germs." , He developed the patent-pending QUDRATECS to eliminate the need ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, ... Table 1-1 ). More than 3.7 billion people under the age of 50 – ... according to WHO's first global estimates of HSV-1 infection . , "The data shocks ...
Breaking Medicine News(10 mins):